Med Business World

Your source for healthcare business

Eye Clinics

First patient treated in the second dose group in Annexin’s RVO study

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company’s clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No…